Latest / Stock Movers / JM Smucker Falls, McDonalds Drops, Novo Nordisk Gains After Report of Parvus Stake
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news, The.
- 0:08Speaker 2: Stock Movers podcast, your roundup of companies making moves in
- 0:13Speaker 2: the stock market, harnessing the power of Bloomberg.
- 0:16Speaker 3: Data Alex Field alongside Paul Sweeney, Let's get to some
- 0:20Speaker 3: of the market drivers within the overall indices. Here Bloomberg
- 0:24Speaker 3: Cross a reporter Isabeli.
- 0:26Speaker 1: Is joining us. All right, what are you looking at?
- 0:28Speaker 1: I'm looking at JM Smuckers. It's not a good day
- 0:31Speaker 1: for the stock down by thirteen percent. So the companies
- 0:33Speaker 1: at US TIFFs that are increasing the cost of their
- 0:36Speaker 1: coffee business would weigh on profit for the coming fiscal years,
- 0:39Speaker 1: estimated at one dollar a share. So Citi analyst said
- 0:42Speaker 1: they were already concerned ahead of the results, but then
- 0:44Speaker 1: when they heard the results, this was even below the
- 0:47Speaker 1: most marrished outlooks.
- 0:48Speaker 3: That they have heard.
- 0:49Speaker 1: So this is a big deal for Smuckers because it
- 0:51Speaker 1: owns Folgers and Cafe Bossello coffee brands. I don't know
- 0:53Speaker 1: if you guys drink those Folgers.
- 0:55Speaker 3: No, because I'm not my grandmother like you just mean
- 1:01Speaker 3: like it for me. By the way, you're supposed to
- 1:03Speaker 3: stay JMS Smucker isn't a jam oh, I see, I see.
- 1:08Speaker 1: Yeah, that's okay, okay, nice age reveal here. So last
- 1:13Speaker 1: fiscal year, the company generated a third of its revenue
- 1:15Speaker 1: from coffee, and since June last year, Smucker all Right
- 1:19Speaker 1: increased its coffee prices three times and they're expected to
- 1:21Speaker 1: boost him again in all this. This is why I've
- 1:24Speaker 1: been hearing a lot of people saying they have to
- 1:25Speaker 1: find alternatives to coffee.
- 1:27Speaker 3: To be fair, my grandma will be one hundred and
- 1:29Speaker 3: twenty or something if she was still alive. So I'm
- 1:31Speaker 3: just saying that's what I think of folters. All right,
- 1:33Speaker 3: let's go to McDonald's.
- 1:35Speaker 1: McDonald So this one is also in the red chairs
- 1:37Speaker 1: are down one and a half percent. So this was
- 1:40Speaker 1: after the burger chain was slapped. It's only cell rating.
- 1:43Speaker 1: We have Redburn Atlantic saying that the shifting consumer patterns
- 1:45Speaker 1: due to weight loss drugs are costs for concerns. So
- 1:49Speaker 1: Redburn gave McDonald's a two notch cut from its previous
- 1:51Speaker 1: by rating.
- 1:52Speaker 3: This was a story two years ago.
- 1:54Speaker 1: You know, we saw this coming, like obviously people want
- 1:56Speaker 1: to be thin and maybe even healthy, then they will
- 1:59Speaker 1: cut down on fast in sweets and donuts.
- 2:01Speaker 3: So this is what we were all worried about that
- 2:03Speaker 3: didn't happen for the last year, and now it's happening.
- 2:05Speaker 3: I think it's this is concrete.
- 2:07Speaker 1: It's their first celebrating and other analysts remain largely split.
- 2:10Speaker 1: McDonald's as twenty two bio equivalent ratings eighteen hold in
- 2:13Speaker 1: an average price are got have thre hundred thirty two,
- 2:16Speaker 1: so that analysts there said that McDonalds can see as
- 2:19Speaker 1: much as four hundred and twenty eight million dollars in
- 2:21Speaker 1: animal impact to revenue.
- 2:23Speaker 3: So number two and number two with a coke. It's
- 2:25Speaker 3: been my order since I was fourteen. This is really true.
- 2:28Speaker 3: So when we were in DC, well, he went to Shakeshack.
- 2:30Speaker 3: We are in DC. He gets to a burger, finishes
- 2:32Speaker 3: it in five minutes and we're we're eating the salad,
- 2:34Speaker 3: peeda thins and the olives and the tazeki. Anyway, yep,
- 2:38Speaker 3: we direst And speaking of Novo Nordisk, this one is
- 2:41Speaker 3: also interesting.
- 2:42Speaker 1: But it's in the gree and up by almost five
- 2:44Speaker 1: percent or more than five percent, So that's the highest
- 2:46Speaker 1: level in two months, and it comes after a report
- 2:49Speaker 1: from activist hedge fund Parvos Asset Management building a stake,
- 2:52Speaker 1: and this comes after we know that the company has
- 2:55Speaker 1: really been struggling, and it seems like Parvos is interested
- 2:57Speaker 1: in influencing the appointment of the You see, Oh so
- 3:01Speaker 1: Novo Lasmad replaced CEO, which shocked everyone because the company's
- 3:04Speaker 1: culture is very close knit. They've only had five CEOs
- 3:07Speaker 1: in their century long history. But now investors seem to
- 3:10Speaker 1: be cheering the move. Because novosdrugs are ozembic and regovid,
- 3:13Speaker 1: they become household names. But I've struggled to just really
- 3:15Speaker 1: make it big and compete with the arrivals.
- 3:18Speaker 2: The Stock Movers podcast from Bloomberg Radio. Check back with
- 3:22Speaker 2: us throughout the day for the latest roundup of companies
- 3:25Speaker 2: making news on Wall Street and for the latest market
- 3:28Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 3:32Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 3:36Speaker 2: the Bloomberg Business app.